Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer

SAN DIEGO & BERLIN--(BUSINESS WIRE)--Vividion announced that the first patient has been dosed in a Phase Ib combination clinical trial for VVD-214, an investigational oral WRN inhibitor.